Chiusura precedente | 4,7680 |
Aperto | 4,7800 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 4,6080 - 4,7800 |
Intervallo di 52 settimane | 4,4200 - 18,9200 |
Volume | |
Media Volume | 388.107 |
Capitalizzazione | 666,35M |
Beta (5 anni mensile) | 1,01 |
Rapporto PE (ttm) | 5,97 |
EPS (ttm) | 0,7800 |
Prossima data utili | 04 mag 2023 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 10,10 |
Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales and €29.6 million of COVID-19 vaccine sales€246.5 million of Other Revenues, primarily driven by revenue recognition related to previous COVID-19 vaccine supply agreements Strong cash position of €289.4 million at December 31, 2022 Raised over €190 million in equity: €102.9 million of gross proceed
VALNEVA Declaration of shares and voting rightsFebruary 28, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change wa
Saint-Herblain (France), March 2, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001. As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with regulators. On Febru